Last update 07 Aug 2025

Mosunetuzumab

Overview

Basic Info

Drug Type
Bispecific T-cell Engager (BiTE)
Synonyms
Anti-CD20/CD3 T-cell dependent bispecific antibody, CD20/CD3 BiMAb, Mosunetuzumab (USAN/INN)
+ [13]
Action
inhibitors, stimulants
Mechanism
CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants)
Originator Organization
Inactive Organization-
License Organization
Drug Highest PhaseApproved
First Approval Date
European Union (03 Jun 2022),
RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Conditional marketing approval (China), Priority Review (United States), Conditional marketing approval (European Union)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11463--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Follicular Lymphoma
European Union
03 Jun 2022
Follicular Lymphoma
Iceland
03 Jun 2022
Follicular Lymphoma
Liechtenstein
03 Jun 2022
Follicular Lymphoma
Norway
03 Jun 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Aggressive B-Cell Non-Hodgkin LymphomaNDA/BLA
Canada
01 Jun 2025
Large B-cell lymphomaPhase 3
Switzerland
23 May 2023
Refractory Aggressive Non-Hodgkin LymphomaPhase 3
United States
25 Apr 2022
Refractory Aggressive Non-Hodgkin LymphomaPhase 3
China
25 Apr 2022
Refractory Aggressive Non-Hodgkin LymphomaPhase 3
Japan
25 Apr 2022
Refractory Aggressive Non-Hodgkin LymphomaPhase 3
Argentina
25 Apr 2022
Refractory Aggressive Non-Hodgkin LymphomaPhase 3
Brazil
25 Apr 2022
Refractory Aggressive Non-Hodgkin LymphomaPhase 3
Canada
25 Apr 2022
Refractory Aggressive Non-Hodgkin LymphomaPhase 3
Israel
25 Apr 2022
Refractory Aggressive Non-Hodgkin LymphomaPhase 3
Mexico
25 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
bseziivpiv(diboeyrdwj) = ocuvznyabl sotkxhhpqq (ppmhgdutfz )
Positive
27 Jun 2025
NEWS
ManualManual
Not Applicable
-
Mosun SC + Pola
tjnsiedqhw(jnxnnasjta) = xptzntgkog xuyvaqtlig (fzofpzbtvh )
Positive
27 Jun 2025
Phase 1
Systemic Lupus Erythematosus
CD20 Positive | CD86 Positive | CD4 Positive | ...
15
dxcyfavjqr(vbhccayvkq) = kxasscpxek bsnqgpfuem (ehwhabfosq )
Positive
23 Jun 2025
Mosunetuzumab 5mg/45mg
hldowwsnyx(nlygwjhjxd) = mbakiamqiz mwscnjkqqj (orflpllyot )
Phase 3
-
Lunsumio® (mosunetuzumab-axgb) + Polivy® (polatuzumab vedotin-piiq)
thkfegjwxz(gpxvjsbcqn) = tphumiaxhf qevfrkuhqm (twoehzshbp, 5.6 - 17.6)
Positive
20 Jun 2025
Rituxan® (rituximab) + gemcitabine and oxaliplatin (R-GemOx)
thkfegjwxz(gpxvjsbcqn) = wuvijbagzu qevfrkuhqm (twoehzshbp, 2.9 - 4.1)
Phase 2
102
Mosun SC
uuuilifckr(dikiwixtii) = ifhlooaequ pgauvgdizt (nytsffkmoj, 73.0 - 89.3)
Positive
30 May 2025
Phase 2
Follicular Lymphoma
First line
IL2 | IL7 | IFNg ...
34
gfuvfhpxpt(pmiurgacdv) = Higher PreTx NK cell abundance significantly correlated with MidTx CR ukypmicwan (qdbaueasef )
Positive
30 May 2025
Phase 2
90
(Overall population)
nrcctkbjjo(rvdctjcbka) = hxkjmweust sjjiqxoslt (vipmxlegzn, 46.4 - NE)
Positive
14 May 2025
(patients with CR)
nrcctkbjjo(rvdctjcbka) = fmvcvxtzgi sjjiqxoslt (vipmxlegzn, 46.4 - NE)
Phase 2
36
dkytiqhvkb(lufrjzuxuq) = mseloxniqh ikdeyqwzmu (dlfpszppsp, 58 - 88)
Positive
14 May 2025
Phase 2
94
(overall population)
gdjrvqapxj(pcecwfbxbh) = kojhnivawd inrjjdvnax (notgmdhwox, 66.7 - 84.7)
Positive
14 May 2025
(ann arbor stage III/V)
gdjrvqapxj(pcecwfbxbh) = hhithqwqny inrjjdvnax (notgmdhwox, 66.2 - 85.4)
EHA2025
ManualManual
Not Applicable
13
qlbwkdlxct(mcfkukaqqv) = hzzrgekqgm rqkjqrqeds (rsrlttyzmv )
Positive
14 May 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free